English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

agent dasatinib in this case of CBF leukemia provides a rationale for its combination with standard chemotherapy, and recently the German–Austrian AMLSG Cooperative Group has initiated a phase II clinical study in patients with newly diagnosed CBF AML. For patients with relapsed RUNX1/RUNX1T1-positive leukemia and comorbidities or a reduced performance status precluding aggressive therapy, a trial with single-agent dasatinib may be warranted.

The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma